Diabetes, endocrinology, and metabolism
GALIP: effect of the GLP1 receptor agonist Lixisenatide in pancreas transplantation
GALIP is a phase 2 safety and efficacy study. When activated, glucagon-like protein 1 (GLP1) receptor stimulates the production and release of insulin from the pancreas. It is hoped that the GLP1 receptor agonist Lixisenatide will improve prognosis in pancreas transplantation.